Eagle Pharmaceuticals, Inc.

NasdaqGM:EGRX Stock Report

Market Cap: US$66.0m

Eagle Pharmaceuticals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Eagle Pharmaceuticals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Sep 21
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Jul 13
Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

Jun 21
Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Oct 27
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Oct 12

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Sep 27

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Aug 18

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Aug 15
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Aug 09

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Jul 06
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Apr 29
Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?

Dec 16
Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?

Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package

Jul 06
Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package

Eagle Pharmaceuticals: A Potential Reopening Play

Jun 16

Eagle Pharmaceuticals EPS misses by $0.49, misses on revenue

May 10

Eagle Pharma's Treakisym RTD + rituximab OK'd in Japan for large b-cell lymphoma

Apr 30

Eagle Pharmaceuticals (NASDAQ:EGRX) Could Easily Take On More Debt

Apr 15
Eagle Pharmaceuticals (NASDAQ:EGRX) Could Easily Take On More Debt

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 55% Above Its Share Price

Mar 25
Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 55% Above Its Share Price

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eagle Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqGM:EGRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202325812-9-9N/A
3/31/2023267-33434N/A
12/31/2022317365151N/A
9/30/2022298212121N/A
6/30/2022272233536N/A
3/31/20222463611N/A
12/31/2021172-92828N/A
9/30/202117963940N/A
6/30/2021189184444N/A
3/31/2021183145657N/A
12/31/2020188124949N/A
9/30/202018652627N/A
6/30/2020177-53132N/A
3/31/202019223233N/A
12/31/2019196145556N/A
9/30/2019204269797N/A
6/30/2019214429090N/A
3/31/2019216387374N/A
12/31/2018213325252N/A
9/30/2018204283740N/A
6/30/2018216304044N/A
3/31/2018207327276N/A
12/31/2017237525459N/A
9/30/20172711006973N/A
6/30/2017246976278N/A
3/31/2017237105N/A38N/A
12/31/201618981N/A53N/A
9/30/201612725N/A-3N/A
6/30/2016943N/A-23N/A
3/31/201660-18N/A-32N/A
12/31/2015663N/A-10N/A
9/30/201554-4N/A-1N/A
6/30/201551-3N/A-1N/A
3/31/2015512N/A7N/A
12/31/201420-21N/A-22N/A
9/30/201419-20N/A-14N/A
6/30/201417-11N/A-7N/A
3/31/201420-9N/A-5N/A
12/31/201318-11N/A-4N/A
9/30/201314-10N/A-6N/A
6/30/201310-14N/A-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if EGRX's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if EGRX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if EGRX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if EGRX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if EGRX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EGRX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.